Catalog No.S2605 Synonyms: CV-2619
Molecular Weight(MW): 338.44
Idebenone is a synthetic analog of coenzyme Q10 (CoQ10) and a brain stimulant.
Purity & Quality Control
Choose Selective ROS Inhibitors
|Description||Idebenone is a synthetic analog of coenzyme Q10 (CoQ10) and a brain stimulant.|
Idebenone effectively protects from retinal cell injury after oxidative stress or hypoglycemia, whereas the protection afforded after postincubation of both antioxidants is decreased. Idebenone attenuates delayed retinal cell damage, mediated by chemical ischemia.  Idebenone, a centrally active antioxidant used to treat multiinfarct dementia, protects cells from this form of glutamate-induced cytotoxicity in vitro. Idebenone provides significant protection against the neuronal degeneration induced by intrastriatal injection of kainic acid and quisqualic acid, but not the NMDA receptor agonist, quinolinic acid. 
|In vivo||Idebenone prevents the behavioural deficits in Y-maze and water maze, but not passive avoidance, tasks in A beta-(1-42)-infused rats when they are repeatedly administered by mouth once a day from 3 days before the start of A beta infusion to the end of behavioural experiments.  Idebenone (100 and 300 mg/kg) is orally administered to rats for 3 days, it increases the state 3 respiration stimulated by ADP, slightly decreasez the state 4 respiration after the consumption of ADP and resultz in a significant increase of the respiratory control index (RCI) by 14-19% for glutamate oxidation and 10-17% for succinate oxidation, respectively. Idebenone significantly suppresses by about 10% the non-respiratory oxygen consumption, which closely associated with non-enzymatic reactions such as lipid peroxidation, membrane lysis and swelling of mitochondria. |
|In vitro||DMSO||68 mg/mL (200.92 mM)|
|Ethanol||68 mg/mL (200.92 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT00229632||Completed||Friedreich Ataxia||National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)||September 23, 2005||Phase 2|
|NCT01854359||Enrolling by invitation||Multiple Sclerosis|Primary Progressive Multiple Sclerosis||National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)||February 22, 2013||Phase 1|Phase 2|
|NCT02814019||Recruiting||Duchenne Muscular Dystrophy (DMD)||Santhera Pharmaceuticals||September 2016||Phase 3|
|NCT02887443||Completed||Drug-Drug Interaction||Santhera Pharmaceuticals||September 2016||Phase 1|
|NCT02771379||Not yet recruiting||Lebers Hereditary Optic Neuropathy (LHON)||Santhera Pharmaceuticals||June 2016||--|
|NCT02774005||Recruiting||Lebers Hereditary Optic Neuropathy (LHON)||Santhera Pharmaceuticals||May 2016||Phase 4|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.